NYSE:MNK Mallinckrodt (MNK) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free MNK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.07▼$0.1350-Day Range$0.14▼$0.7552-Week Range$0.75▼$6.42Volume39,227 shsAverage Volume2.62 million shsMarket Capitalization$1.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesInsider TradesOwnershipSocial MediaStock AnalysisEarningsHeadlinesInsider TradesOwnershipSocial Media Get Mallinckrodt alerts: Email Address Ad DTIIf you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! Click here to unlock the Income Glitch training workshop for free. About Mallinckrodt Stock (NYSE:MNK)Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.Read More Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. MNK Stock News HeadlinesApril 25, 2024 | reuters.comBankruptcy allowed Mallinckrodt to end Acthar royalties, 3rd Circ. rulesApril 14, 2024 | finanznachrichten.deMallinckrodt plc: Mallinckrodt Announces 2024 Extracorporeal Immunomodulation AwardApril 29, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… March 26, 2024 | finance.yahoo.comMallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 GuidanceMarch 4, 2024 | finanznachrichten.deMallinckrodt plc: Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty BrandsMarch 4, 2024 | finance.yahoo.comMallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty BrandsMarch 1, 2024 | markets.businessinsider.comMallinckrodt Says FDA Grants SNDA For Acthar Gel Single-Dose Pre-Filled SelfJect InjectorFebruary 24, 2024 | benzinga.comMallinckrodt Stock (OTC:MCKPF) Dividends: History, Yield and DatesApril 29, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.February 21, 2024 | finanznachrichten.deMallinckrodt plc: Mallinckrodt Presents Data on Real-World Outcomes with THERAKOS CELLEX Photopheresis System Treatment at the 2024 Tandem MeetingsFebruary 3, 2024 | msn.comMallinckrodt Announces Executive Appointments and Incentive PlansJanuary 31, 2024 | morningstar.comMallinckrodt PLC Ordinary Shares - NewJanuary 9, 2024 | msn.comMallinckrodt to discontinue StrataGraft due to slow uptakeDecember 27, 2023 | finance.yahoo.comMallinckrodt Earns Top Score in Human Rights Campaign Foundation's 2023-2024 Corporate Equality IndexDecember 7, 2023 | sg.finance.yahoo.comMallinckrodt Announces FDA Clearance of the INOmax® EVOLVE™ DS Delivery System and Approval of the INOmax® (nitric oxide) Mini-CylinderDecember 1, 2023 | msn.comMallinckrodt Avoids $40 Million SEC Fine in Medicaid Overcharge CaseNovember 16, 2023 | finance.yahoo.comMallinckrodt plc (in Examinership) Reports Third Quarter 2023 Financial ResultsNovember 15, 2023 | msn.comMallinckrodt emerges from bankruptcyNovember 14, 2023 | finance.yahoo.comMallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11October 11, 2023 | msn.comMallinckrodt sees emerging from Chapter 11 by end of yearOctober 11, 2023 | msn.comMallinckrodt Bankruptcy Plan Gets Approval, Will Wipe Out $1 Billion in Opioid PaymentsOctober 11, 2023 | finance.yahoo.comMallinckrodt Approved to End Bankruptcy, Reduce Opioid PaymentsOctober 10, 2023 | reuters.comMallinckrodt gets court approval for restructuring, $1 bln cut to opioid settlementOctober 10, 2023 | finance.yahoo.comMallinckrodt plc (in examinership) Receives U.S. Court Approval for Financial Restructuring PlanSeptember 20, 2023 | msn.comFirm Retention Summary: MallinckrodtSeptember 20, 2023 | msn.comDrug giant Mallinckrodt enters second Irish ExaminershipSeptember 19, 2023 | msn.comBankrupt Drugmaker Mallinckrodt Considers Sale of Opioid BusinessSee More Headlines Receive MNK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/04/2020Today4/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:MNK CUSIPN/A CIK1567892 Webwww.mallinckrodt.com Phone(531) 696-0000FaxN/AEmployees2,700Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($116.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net Margins-82.59% Pretax MarginN/A Return on Equity20.32% Return on Assets2.49% Debt Debt-to-Equity Ratio1.18 Current Ratio0.57 Quick Ratio0.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$47.48 per share Price / Book0.00Miscellaneous Outstanding Shares13,170,000Free Float13,131,000Market Cap$1.58 million OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMark C. TrudeauPresident, Chief Executive Officer & DirectorBryan M. ReasonsChief Financial Officer & Executive Vice PresidentSteven Joseph RomanoChief Scientific Officer & Executive VPBabatunde Adekunle OtulanaChief Medical Officer & Senior Vice PresidentMichele RobertsonChief Compliance Officer & Senior Vice PresidentKey CompetitorsNeuBase TherapeuticsNASDAQ:NBSE180 Life SciencesNASDAQ:ATNFInMed PharmaceuticalsNASDAQ:INMHistogenNASDAQ:HSTOPanbela TherapeuticsNASDAQ:PBLAView All Competitors MNK Stock Analysis - Frequently Asked Questions How were Mallinckrodt's earnings last quarter? Mallinckrodt plc (NYSE:MNK) issued its quarterly earnings data on Tuesday, August, 4th. The company reported $1.89 earnings per share for the quarter, beating analysts' consensus estimates of $1.34 by $0.55. The business earned $700.90 million during the quarter, compared to analysts' expectations of $630.19 million. Mallinckrodt had a positive trailing twelve-month return on equity of 20.32% and a negative net margin of 82.59%. The company's revenue was down 14.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.53 earnings per share. Read the conference call transcript. What other stocks do shareholders of Mallinckrodt own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Endo International (ENDP), Teva Pharmaceutical Industries (TEVA), Gerdau (GGB), AT&T (T), Alibaba Group (BABA), Advanced Micro Devices (AMD). This page (NYSE:MNK) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlaceThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mallinckrodt plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
